# Xenon to Present at Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/XENE/xenon-to-present-at-upcoming-investor-conferences
Ticker: XENE
Company: Xenon
Source: Xenon
Published: 2026-04-15 12:30 EST
Original Source URL: https://investor.xenon-pharma.com
## Summary

VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need,

## Article Body
VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need,
## Recent Company News
- 2026-05-07 20:01 EST — [Xenon Reports Q1 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/XENE/xenon-reports-q1-2026-financial-results-and-provides-business-update) — Source: Xenon
- 2026-05-01 20:01 EST — [Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Xenon
- 2026-04-30 20:01 EST — [Xenon to Report Q1 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/XENE/xenon-to-report-q1-2026-financial-results-on-may-7-2026) — Source: Xenon
- 2026-04-19 22:00 EST — [Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)](https://biopharmsignal.com/news/XENE/results-from-the-phase-3-x-tole2-study-evaluating-azetukalner-a-novel-potent-kv7-channel-opener-in-adults-with-focal-onset-seizures-fos) — Source: Xenon
- 2026-04-19 22:00 EST — [Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting](https://biopharmsignal.com/news/XENE/xenon-presents-azetukalner-phase-3-x-tole2-study-results-and-48-month-long-term-data-in-focal-onset-seizures-at-2026-aan-annual-meeting) — Source: Xenon
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)